(new: entry, closing price)
FRANKFURT (dpa-AFX) – The shares of SCHOTT Pharma initially went up and down on Thursday according to the annual figures and outlook. As the market progressed, however, it continued to decline steadily until it reached a record low of 23.60 euros in late trading. In the end, the special packaging manufacturer’s papers lost 5.6 percent to 24.54 euros. The Gerresheimer competitor went on the floor in September 2023 at an issue price of 27 euros.
A trader spoke of a “mixed set of figures” at Schott Pharma, with solid targets for the new financial year and confirmed medium-term goals.
UBS analyst Olivier Calvet, on the other hand, called the operating earnings target (Ebitda) for 2024/25 somewhat disappointing, while analyst James Vane-Tempest from Jefferies complained that the margin outlook fell short of expectations. He also pointed out that the forecasts for the 2024/25 financial year were slightly below those given by Schott Pharma over the course of the year. This was “to some extent expected by the market based on the figures for the third quarter,” he added.
Regardless of the numbers, UBS expert Calvet had expected at least “moderate price gains” since the share price had suffered significant losses in the past few months. There was a sharp decline, especially after the record high at the beginning of March at 43.40 euros. A slight recovery began in mid-November. So far this year there has been a decline of around 27 percent; Gerresheimer lost around 20 percent./ck/ngu/edh/jha/
Selected leverage products on Gerresheimer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Gerresheimer
The leverage must be between 2 and 20
Advertising